Primary Adrenal Insufficiency After COVID-19 Infection
Background/Objective: The multisystemic effects of COVID-19 are becoming evident. In the adrenal gland, adrenal hemorrhage and infarction after COVID-19 infection have been reported. Our objective is to present a case of autoimmune adrenal insufficiency diagnosed after COVID-19 infection, without th...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | AACE Clinical Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S237606052100119X |
| _version_ | 1811273440403914752 |
|---|---|
| author | Julienne Sánchez, MD Melissa Cohen, MD Joseph L. Zapater, MD PhD Yuval Eisenberg, MD |
| author_facet | Julienne Sánchez, MD Melissa Cohen, MD Joseph L. Zapater, MD PhD Yuval Eisenberg, MD |
| author_sort | Julienne Sánchez, MD |
| collection | DOAJ |
| description | Background/Objective: The multisystemic effects of COVID-19 are becoming evident. In the adrenal gland, adrenal hemorrhage and infarction after COVID-19 infection have been reported. Our objective is to present a case of autoimmune adrenal insufficiency diagnosed after COVID-19 infection, without the evidence of a hemorrhage or an infarction. Case Report: A 64-year-old woman with hypothyroidism and type 2 diabetes presented with a 1-week history of abdominal pain, nausea, and vomiting. She had experienced asymptomatic COVID-19 infection 5 months prior and reported an unintentional 30-lb weight loss. The home medications included enalapril, atorvastatin, and levothyroxine. A physical examination was notable for hypotension, epigastric tenderness, and mucocutaneous hyperpigmentation. Laboratory tests revealed a serum sodium level of 117 mmol/L (range, <20 mmol/L), thyroid-stimulating hormone level of 0.33 μIU/mL (range, 0.35-4.00 μIU/mL), free thyroxine level of 1.4 ng/dL (range, 0.6-1.7 ng/dL), serum osmoles of 253 mOsm/kg (range, 279-300 mOsm/kg), urine osmoles of 324 mOsm/kg (range, 300-900 mOsm/kg), and urine sodium level of 104 mmol/L. The morning cortisol level was 2.6 μg/dL (reference [ref], >18 μg/dL). This was followed by a high-dose, 250-μg adrenocorticotropic hormone (ACTH) stimulation test, which revealed that the cortisol level was 2.3, 2.9, and 2.6 μg/dL (ref, >18 μg/dL) at baseline, 30 minutes, and 60 minutes, respectively. The ACTH level was 1944 pg/mL (range, 7.2-63.3 pg/mL), the aldosterone level was <3.0 ng/dL (range, 4.0-31.0 ng/dL), and anti-21-hydroxylase antibody was present (ref, negative). A computed tomography scan of the adrenals was unremarkable. Hypotension and hyponatremia resolved after initiation of intravenous hydrocortisone, and she was discharged on hydrocortisone and fludrocortisone. Discussion: The patient’s symptoms, elevated ACTH level, low cortisol level, and presence of 21-hydroxylase antibodies were consistent with Addison disease. COVID-19 might have contributed to rapid, clinically relevant disease progression after the infection. Conclusion: The development of autoimmune Addison disease in the patient might be related to the prior COVID-19 infection. |
| first_indexed | 2024-04-12T22:59:15Z |
| format | Article |
| id | doaj.art-747ada2a1b1e49b0b14ad94582078a39 |
| institution | Directory Open Access Journal |
| issn | 2376-0605 |
| language | English |
| last_indexed | 2024-04-12T22:59:15Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | AACE Clinical Case Reports |
| spelling | doaj.art-747ada2a1b1e49b0b14ad94582078a392022-12-22T03:13:07ZengElsevierAACE Clinical Case Reports2376-06052022-03-01825153Primary Adrenal Insufficiency After COVID-19 InfectionJulienne Sánchez, MD0Melissa Cohen, MD1Joseph L. Zapater, MD PhD2Yuval Eisenberg, MD3Department of Medicine, University of Illinois at Chicago, Chicago, IllinoisDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IllinoisDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, IllinoisDivision of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, Chicago, Illinois; Address correspondence to Yuval Eisenberg, MD, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Illinois at Chicago, 835 South Wolcott Avenue, Suite 625E (M/C 640), Chicago, IL 60612.Background/Objective: The multisystemic effects of COVID-19 are becoming evident. In the adrenal gland, adrenal hemorrhage and infarction after COVID-19 infection have been reported. Our objective is to present a case of autoimmune adrenal insufficiency diagnosed after COVID-19 infection, without the evidence of a hemorrhage or an infarction. Case Report: A 64-year-old woman with hypothyroidism and type 2 diabetes presented with a 1-week history of abdominal pain, nausea, and vomiting. She had experienced asymptomatic COVID-19 infection 5 months prior and reported an unintentional 30-lb weight loss. The home medications included enalapril, atorvastatin, and levothyroxine. A physical examination was notable for hypotension, epigastric tenderness, and mucocutaneous hyperpigmentation. Laboratory tests revealed a serum sodium level of 117 mmol/L (range, <20 mmol/L), thyroid-stimulating hormone level of 0.33 μIU/mL (range, 0.35-4.00 μIU/mL), free thyroxine level of 1.4 ng/dL (range, 0.6-1.7 ng/dL), serum osmoles of 253 mOsm/kg (range, 279-300 mOsm/kg), urine osmoles of 324 mOsm/kg (range, 300-900 mOsm/kg), and urine sodium level of 104 mmol/L. The morning cortisol level was 2.6 μg/dL (reference [ref], >18 μg/dL). This was followed by a high-dose, 250-μg adrenocorticotropic hormone (ACTH) stimulation test, which revealed that the cortisol level was 2.3, 2.9, and 2.6 μg/dL (ref, >18 μg/dL) at baseline, 30 minutes, and 60 minutes, respectively. The ACTH level was 1944 pg/mL (range, 7.2-63.3 pg/mL), the aldosterone level was <3.0 ng/dL (range, 4.0-31.0 ng/dL), and anti-21-hydroxylase antibody was present (ref, negative). A computed tomography scan of the adrenals was unremarkable. Hypotension and hyponatremia resolved after initiation of intravenous hydrocortisone, and she was discharged on hydrocortisone and fludrocortisone. Discussion: The patient’s symptoms, elevated ACTH level, low cortisol level, and presence of 21-hydroxylase antibodies were consistent with Addison disease. COVID-19 might have contributed to rapid, clinically relevant disease progression after the infection. Conclusion: The development of autoimmune Addison disease in the patient might be related to the prior COVID-19 infection.http://www.sciencedirect.com/science/article/pii/S237606052100119XSARS-CoV-2COVID-19adrenal insufficiencyAddison disease |
| spellingShingle | Julienne Sánchez, MD Melissa Cohen, MD Joseph L. Zapater, MD PhD Yuval Eisenberg, MD Primary Adrenal Insufficiency After COVID-19 Infection AACE Clinical Case Reports SARS-CoV-2 COVID-19 adrenal insufficiency Addison disease |
| title | Primary Adrenal Insufficiency After COVID-19 Infection |
| title_full | Primary Adrenal Insufficiency After COVID-19 Infection |
| title_fullStr | Primary Adrenal Insufficiency After COVID-19 Infection |
| title_full_unstemmed | Primary Adrenal Insufficiency After COVID-19 Infection |
| title_short | Primary Adrenal Insufficiency After COVID-19 Infection |
| title_sort | primary adrenal insufficiency after covid 19 infection |
| topic | SARS-CoV-2 COVID-19 adrenal insufficiency Addison disease |
| url | http://www.sciencedirect.com/science/article/pii/S237606052100119X |
| work_keys_str_mv | AT juliennesanchezmd primaryadrenalinsufficiencyaftercovid19infection AT melissacohenmd primaryadrenalinsufficiencyaftercovid19infection AT josephlzapatermdphd primaryadrenalinsufficiencyaftercovid19infection AT yuvaleisenbergmd primaryadrenalinsufficiencyaftercovid19infection |